Cyclosporine A in veterinary ophthalmology

Veterinary Ophthalmology

Volumn 1, Issue 4, 1998, Pages 181-187

  Gilger, Brian C ^a   Allen, Janice B ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Animal; Cyclosporine A; Indications; Ocular; Pharmacology

Indexed keywords

ANIMALIA;

EID: 0011047577     PISSN: 14635216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-5224.1998.00039.x     Document Type: Review

References (53)

1. Granelli-Piperno A. Cellular mode of action of cyclosporin A. In: T-Cell Directed Immunointervention (ed. Bach JF), Blackwell Scientific Publishers, Oxford, 1993; 3-24.
2. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunology Today 1992; 13: 136-141.
3. George RK, Chan CC, Whitcup SM et al. Ocular immunopathology of Behcet's disease. Survey of Ophthalmology 1997; 42: 157-162.
4. Belin MW, Bouchard CS, Frantz S et al. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989; 96: 1144-1150.
5. Gratzek AT, Kaswan RL, Martin CL et al. Ophthalmic cyclosporine in equine keratitis and keratouveitis: 11 cases. Equine Veterinary Journal 1995; 27: 327-333.
6. Holland EJ, Olsen TW, Ketcham JM et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993; 12: 413-419.
7. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Survey of Ophthalmology 1991; 35: 369-385.
8. Jackson P, Kaswan R, Merideth RE et al. Chronic superficial keratitis in dogs: a placebo controlled trial of topical cyclosporine treatment Progress in Veterinary and Comparative Ophthalmology 1991; 1: 269-275.
9. Johnson CK, Lockwood PW, Weingarten AJ. Cyclosporine ointment for KCS. Small Animal Medicine and Surgery 1994; 7: 1-4.
10. Kaswan RL, Salisbury MA, Ward D. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Archives of Ophthalmology 1989; 107: 1210-1216.
11. Mathews AG. Cyclosporine A and the equine cornea. Equine Veterinary Journal 1995; 27: 320-321.
12. Kern TJ. Topical cyclosporine therapy for keratoconjunctivitis sicca in dogs. Cornell Veterinarian 1989; 79: 207-209.
13. Morgan RV, Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 1991; 199: 1043-1046.
14. Nussenblatt RB, Palestine AG, Chan CC et al. Randomized, double-masked study of cyclosporine compared to prednisone in the treatment of endogenous uveitis. American Journal of Ophthalmology 1991; 112: 138-146.
15. Olivero DK, Davidson MG, English RV et al. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 1991; 199: 1039-1042.
16. Read RA. Treatment of canine nictitans plasmacytic conjunctivitis with 0.2% cyclosporin ointment. Journal of Small Animal Practice 1995; 36: 50-56.
17. Read RA, Barnett KC, Sansom J. Cyclosporine-responsive keratoconjunctivitis in the cat and horse. Veterinary Record 1995; 137: 170-171.
18. Salisbury JD, Gebhardt BM. Suppression of corneal allograft rejection by cyclosporin A. Archives of Ophthalmology 1981; 99: 1640-1643.
19. Salisbury MA, Kaswan RL, Ward DA et al. Topical application of cyclosporine in the management of keratoconjunctivitis sicca in dogs. Journal of the American Animal Hospital Association 1990; 26: 269-274.
20. Sansom J, Barnett KC, Neumann W et al. Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial. Veterinary Record 1995; 137: 504-507.
21. Williams DL, Hoey AJ, Smitherman P. Comparison of topical cyclosporin and dexamethasone for the treatment of chronic superficial keratitis in dogs. Veterinary Record 1995; 137: 635-639.
22. Kay JE. Inhibitory effects of cyclosporin A on lymphocyte activation. In: Cyclosporine: Mode of Action and Clinical Application (ed. Thomson AW), Kluuver Academic Publishers, Dordrecht, 1989; 1-23.
23. Thompson AW. Immunological effects of cyclosporin A. In: T-Cell-Directed Immunointervention (ed. Bach JF), Blackwell Scientific Publications, Oxford, 1993; 27-48.
24. Franz G, Loukeris TG, Dialektaki G et al. Mobile Minos elements from Drosophila hydei encode a two-exon transposase with similarity to the paired DNA-binding domain. Proceedings of the National Academy of Sciences of the USA 1994; 91: 4746-4750.
25. Grevel J, Kahan BD. Pharmacokinetics of cyclosporin A. In: Cyclosporin: Mode of Action and Clinical Application (ed. Thomson AW), Kluuver Academic Publishers, Dordrecht, 1989; 252-266.
26. Keown PA. Pharmacokinetics, drug interactions, and analytical measurement of cyclosporine. In: T-Cell-Directed Immunointervention (ed. Bach JP), Oxford: Blackwell Scientific Publications, 1993: 51-76.
27. Kaswan RL Intraocular penetration of topically applied cyclosporine. Transplantation Proceedings 1988; 20: 650-655.
28. Mosteller MW, Gebhardt BM, Hamilton AM et al. Penetration of topical cyclosporin into the rabbit cornea, aqueous humor, and serum. Archives of Ophthalmology 1985; 103: 101-102.
29. BenEzra D, Maftzir G. Ocular penetration of cyclosporin A, the rabbit eye. Investigative Ophthalmology and Visual Science 1990; 31: 1362-1366.
30. BenEzra D, Maftzir G. Ocular penetration of cyclosporine A in the rat eye. Archives of Ophthalmology 1990; 108: 584-587.
31. Nussenblatt RB, Dinning WJ, Fujikawa LS et al. Local cyclosporin therapy for experimental autoimmune uveitis in rats. Archives of Ophthalmology 1985; 103: 1559-1562.
32. BenEzra D, Maftizir G, de Courten C et al. Ocular penetration of cyclosporin A. III. The human eye. British Journal of Ophthalmology 1990; 74: 350-352.
33. Kaswan RL, Kaplan HJ. Comparison of the efficacy of unilateral, bilateral, and oral cyclosporine in experimental immunogenic uveitis in rabbits. Transplantation Proceedings 1988; 20: 149-157.
34. Kaswan RL, Kaplan HJ, Martin CL. Topically applied cyclosporine for modulation of induced immunogenic uveitis in rabbits. American Journal of Veterinary Research 1988; 49: 1757-1759.
35. Foets B, Missotten L, Vanderveeren P et al. Prolonged survival of allogeneic corneal grafts in rabbits treated with topically applied cyclosporin A. Systemic absorption and local immunosuppressive effect British Journal of Ophthalmology 1985; 69: 600-603.
36. Gregory CR, Hietala SK, Pedersen NC et al. Cyclosporine pharmacokinetics in cats following topical ocular administration. Transplantation 1989; 47: 516-519.
37. Bounous DI, Carmichael KP, Kaswan RL et al. Effects of ophthalmic cyclosporine on lacrimal gland pathology and function in dogs with keratoconjunctivitis sicca. Veterinary and Comparative Ophthalmology 1995; 5: 5-12.
38. Gilger BC, Andrews J, Wilkie DA et al. Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Veterinary Immunology and Immunopathology 1995; 49: 199-208.
39. Gilger BC, Andrews J, Wilkie DA et al. Lymphocyte proliferation and blood drug levels in dogs with keratoconjunctivitis sicca receiving long-term topical ocular cyclosporine. Veterinary and Comparative Ophthalmology 1996; 6: 125-130.
40. Deeg HJ, Storb R, Gerhard-Miller L et al. Cyclosporin A, a powerful immunosuppressant in vivo and in vitro in the dog, fails to induce tolerance. Transplantation 1980; 29: 230-235.
41. Salisbury MR, Kaswan RL, Brown J. Microorganisms isolated from the corneal surface before and during topical cyclosporine treatment in dogs with keratoconjunctivitis sicca. American Journal of Veterinary Research 1995; 56: 880-884.
42. Osato MS, Roussel TJ, Wilhelmus KR et al. In vitro and in vivo antifungal activity of cyclosporine. In: Cyclosporin: Biological Activity and Clinical Applications (ed. Kohan BD), Gruer and Stratton, New York, 1983; 711-714.
43. Nussenblatt RB, Palestine AG. Cyclosporine: Immunology, pharmacology, and therapeutic uses. Survey of Ophthalmology 1986; 31: 159-169.
44. Mochizuki M, Kawashima H. Effects of FK506, 15-deoyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. Autoimmunity 1990; 8: 37-41.
45. Nussenblatt RB, Scher I. Effects of cyclosporin on T-cell subsets in experimental autoimmune uveitis. Investigative Ophthalmology and Visual Science 1985; 26: 10-14.
46. Ryffel B, Donatsch P, Madorin M et al. Toxicological evaluation of cyclosporin A. Archives of Toxicology 1983; 53: 107-141.
47. White JV, Ravis WR, Nachreiner R et al. Cyclosporine pharmacokinetics in normal and pancreatectomized dogs. Transplantation 1986; 42: 390-394.
48. Enyedi LB, Pearson PA, Ashton P et al. An intravitreal device providing sustained release of cyclosporine and dexamethasone. Current Eye Research 1996; 15: 549-557.
49. Pearson PA, Jaffe GJ, Martin DF et al. Evaluation of a delivery system providing long-term release of cyclosporine. Archives of Ophthalmology 1996; 114: 311-317.
50. Gilger BC, Cutter KV, Allen JB. T-cell subsets and cytokine profiles of eyes with chronic equine recurrent uveitis. Veterinary Immunology and Immunopathology 1998, in press.
51. Cheng CK, Berger AS, Pearson PA, et al. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Investigative Ophthalmology and Visual Science 1995; 36: 442-253.
52. Gilger BC, Cutter KV, Morgan D et al. Long-term toxicity and pharmacology of an intravitreal cyclosporine implant in normal equine eyes. Annual Meeting of the American College of Veterinary Ophthalmologists. Seattle, WA, 1998.
53. Gilger BC, Malok E, Stewart T et al. Effect of an intravitreal cyclosporine implant on H37RA-mTB experimental uveitis in horses. Association for Research in Vision and Ophthalmology 1999, in press.